Insulin-producing cells (IPCs) derived from human embryonic stem cells (hESCs) hold great potential for cell transplantation therapy in diabetes. Tremendous progress has been made in inducing differentiation of hESCs into IPCs in vitro, of which definitive endoderm (DE) protocol mimicking foetal pancreatic development has been widely used. However, immaturity of the obtained IPCs limits their further applications in treating diabetes. Forkhead box O1 (FoxO1) is involved in the differentiation and functional maintenance of murine pancreatic β cells, but its role in human β cell differentiation is under elucidation. Here, we showed that although FoxO1 expression level remained consistent, cytoplasmic phosphorylated FoxO1 protein level increased during IPC differentiation of hESCs induced by DE protocol. Lentiviral silencing of FoxO1 in pancreatic progenitors upregulated the levels of pancreatic islet differentiation-related genes and improved glucose-stimulated insulin secretion response in their progeny IPCs, whereas overexpression of FoxO1 showed the opposite effects. Notably, treatment with the FoxO1 inhibitor AS1842856 displayed similar effects with FoxO1 knockdown in pancreatic progenitors. These effects were closely associated with the mutually exclusive nucleocytoplasmic shuttling of FoxO1 and Pdx1 in the AS1842856-treated pancreatic progenitors. Our data demonstrated a promising effect of FoxO1 inhibition by the small molecule on gene expression profile during the differentiation, and in turn, on determining IPC maturation via modulating subcellular location of FoxO1 and Pdx1. Therefore, we identify a novel role of FoxO1 inhibition in promoting IPC differentiation of hESCs, which may provide clues for induction of mature β cells from hESCs and clinical applications in regenerative medicine.
Introduction
Diabetes mellitus is a chronic noncommunicable disease that seriously endangers public health worldwide. Patients with either type 1 or type 2 diabetes suffer from failure of pancreatic β cells, albeit via different mechanism [1] [2] [3] . Islets transplantation has been proved to be able to reconstruct the islet function in patients with diabetes, but is hampered by immunological rejection and insufficient donor resources that are far from meeting the needs of a large number of the patients [4] . Human embryonic stem cells (hESCs), characterized by the extensive potential of proliferation and differentiation, can be efficiently induced to differentiate into insulin producing cells (IPCs) in vitro by mimicking key developmental events in a stepwise manner, which can solve the problem of donor islet shortage and provide a new solution for cell replacement therapy [5] . Despite tremendous efforts made in the past decade, no fully matured β cells have actually been obtained in vitro, which greatly hinders the further application of the hESC-derived IPCs in diabetes therapy [6] . The problems are mainly concentrated in functional immaturity of the differentiated cells and unclear mechanism of the IPC differentiation. The definitive endoderm (DE) protocol is based on the knowledge of developmental biology in which the differentiation condition mimics the stepwise changes of signaling pathways and gene expression profile during foetal pancreatic β cell development. IPCs, characterized by similar features with pancreatic islet cells except functional maturation, can be successfully induced with the differentiation strategies based on the DE protocol [7] [8] [9] [10] [11] . Therefore, it is necessary to optimize the in vitro differentiation strategies for higher differentiation efficiency and better IPC maturation.
Forkhead box O (FoxO) is highly conserved in evolution and consists of four main members in mammals, including FoxO1, FoxO3, FoxO4 and FoxO6 [12] . FoxO1 is highly expressed in insulin-responsive tissues such as liver and pancreas, and closely involved in metabolic regulation [13] . Knockout of FoxO1 increased the number of β cells derived from mouse pancreatic precursor cells and promoted generation of IPCs from intestinal endocrine precursor cells of mice [14, 15] . Moreover, FoxO1 inhibition enhanced differentiation of human induced pluripotent stem cells derived gut organoid cultures towards functional IPCs [16] and upregulated the expression of β cell markers in IPCs generated from human foetal pancreatic precursor cells [17, 18] in vitro. In addition, overexpression of FoxO1 in mouse pancreatic precursor cells resulted in pancreatic hypoplasia in vivo [19] . Furthermore, FoxO1 is a negative regulator of pancreatic and duodenal homeobox-1 (Pdx1) in adult β cells [20] , and Pdx1 plays a key regulatory role in β cell generation and maturation at embryonic period [21] . Based on these observations, we assume that FoxO1 may be involved in negative regulation in the differentiation of hESCs into functional IPCs.
Post-translational modifications (phosphorylation and acetylation) regulate the transactivation potential and the DNA binding of FoxO1 [22, 23] . FoxO1 is phosphorylated by protein kinase B (PKB/Akt) at S256 upon insulin receptor or insulin-like growth factor 1 receptor stimulation and its binding to 14-3-3 leads to nuclear export and cytoplasmic accumulation [24] [25] [26] . AS1842856, a selective FoxO1 inhibitor, can potently suppress the DNA binding of FoxO1 and its transactivation [26, 27] . AS1842856 inhibited hepatic glucose production in cultured rodent hepatocytes and oral administration of AS1842856 to diabetic db/db mice resulted in a significant decline of fasting blood glucose [26] . However, the effect of AS1842856 on pancreatic β cell ontogenesis has not been examined.
In the present study, we demonstrated that although the expression level of FoxO1 mRNA and protein was unchanged during differentiation of hESCs towards IPCs, silencing of FoxO1 in pancreatic progenitors improved glucose-stimulated insulin secretion (GSIS) response accompanied by a significant upregulation of pancreatic islet developmentrelated genes, whereas overexpression of FoxO1 impaired the GSIS response. In concert with these findings, targeted inhibition of FoxO1 with AS1842856 triggered similar effects with those of FoxO1 knockdown on the IPC differentiation, which was closely associated with nucleocytoplasmic translocation of FoxO1 and Pdx1. Our data may lead to understanding the role of FoxO1 in the process of IPC differentiation from hESCs and help optimize the in vitro induction strategies.
Materials and methods

Culture and differentiation of hESCs
The hESC cell line PKU1.1 was established at the Reproductive Medical Center of Peking University Third Hospital [28] . The modified five-stage DE protocol was applied to culture and induce the in vitro differentiation of hESCs into IPCs as previously described [11] . Cell culture reagents were purchased from Life Technologies (Grand Island, NY, USA) unless otherwise specified. The hESCs (stage 1) were passaged every 5 days by incubation in 1 mg/ml collagenase IV. Thereafter, hESCs were plated on matrigel (1:50; BD Biosciences, Bedford, MA, USA)-coated dishes and induced to differentiate into DE (stage 2) cells by DF12 supplemented with 100 ng/ml activin A (Peprotech, Rocky Hill, NJ, USA) and 1 μM wortmannin (Sigma-Aldrich, St. Louis, MO, USA) for 4 days. The stage-2 cells were cultured in IMDM/F12 with 2 μM retinoic acid (RA, Sigma-Aldrich), 20 ng/ml fibroblast growth factor 7 (FGF7, Peprotech), 50 ng/ml Noggin (Peprotech) and 0.25 μM KAAD-cyclopamine (Calbiochem, San Diego, CA, USA) for 4 days and differentiated into pancreatic progenitor (stage 3) cells. The stage-3 cells were expanded to generate more pancreatic progenitor (stage 4) cells in DMEM (high glucose) with 50 ng/ml epidermal growth factor (EGF, Peprotech) for 4 days. To form IPCs, the stage-4 cells were incubated in DF12 (low glucose) with 10 ng/ml basic FGF, 10 mM nicotinamide and 50 ng/ml exendin-4 (Sigma-Aldrich) for 5 days. For further maturity, the cells were digested by 0.05% trypsin-EDTA and were transferred to ultra-low attachment 6-well plates for 3 days in suspension culture to form clusters.
Lentivirus-mediated transfection
FoxO1 lentiviral vector construction, identification, packaging and titration were completed by Genechem Co. Ltd (Shanghai, China). Lentiviral silencing vector of FoxO1 (LV-si-FoxO1), lentiviral overexpressing vector of FoxO1 (LV-OE-FoxO1) and their respective negative controls were constructed by Genechem. Three FoxO1-targeting oligonucleotides were designed, and one scrambled oligonucleotide served as the negative control. All oligonucleotide sequences are listed in Supplementary Table 1 . The human FoxO1 (NM_002015) coding region was cloned into GV358 vectors (Genechem) for construction of LV-OE-FoxO1. Its respective empty lentiviral vectors that express GFP alone served as the negative control. The stage-3 cells during the IPC differentiation of hESCs were infected with LV-si-FoxO1, LV-OE-FoxO1 and their respective negative control lentiviral vectors according to the manufacturer's instructions, in the presence of 5 μg/ml polybrene at a multiplicity of infection of 50, with optimal infection efficiency occurring at 30-60% confluence. The infected cells were further induced along the differentiation protocol. All experiments were performed at a minimum of three times.
FoxO1 inhibitor treatment
The FoxO1 inhibitor used in the present study, AS1842856 [5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], were obtained from Calbiochem. Cells were treated with AS1842856 (100 nM) or solvent dimethylsulfoxide (DMSO, Sigma-Aldrich) that served as control from stage 3 during the differentiation.
Quantitative real-time RT-PCR
Total RNA was extracted from cells at a specified differentiation stage using a Trizol kit (Life Technologies) and reversely transcribed into cDNA using a First Strand cDNA synthesis Kit (Thermo Fisher Scientific, Fermentas, ON, Canada) according to the manufacturer's instructions. Real-time PCR was performed in triplicate using the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) with QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific). The sample input was normalized against the cycle threshold value of the housekeeping gene GAPDH. The primers were summarized in Supplementary Table 2.
Western blot analysis
Total proteins were obtained from cells by radioimmune precipitation assay (RIPA) lysis buffer containing proteinase and phosphatase inhibitors (Applygen Technologies, Beijing, China). Nuclear and cytoplasmic proteins were separated using Nuclear and Cytoplasmic Protein Extraction Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. An aliquot of 30 µg protein/lane was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 10% gels and transferred onto nitrocellulose membranes. The membranes were then blocked with 5% bovine serum albumin in TBST for 1 h and incubated at 4°C overnight with primary antibodies: rabbit anti-phosphorylated FoxO1 (p-FoxO1) (1:1 000; Cell Signaling Technology, Beverly, MA, USA), rabbit anti-FoxO1 (1:1 000, Cell Signaling Technology), goat anti-Pdx1 (1:1 000; Abcam, Cambridge, MA, USA), mouse anti-GAPDH (1:1 000; Zhongshan Biotechnology, Beijing, China), and mouse anti-TATA binding protein (TBP) (1:1 000, Abcam). After three washes, the blots were incubated with IRDye 800CW-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (both at 1:10 000 dilution; LI-COR Biosciences, Lincoln, NE, USA) for 1 h. Protein bands were visualized with Odyssey 290 infrared imaging system (LI-COR Biosciences). The density of the products was quantified using ImageJ software (NIH, Bethesda, MD, USA).
Insulin secretion assay
The stage 5-clusters in suspension culture were rinsed twice in KRBH buffer and preincubated for 1 h in KRBH buffer at 37°C. The buffer was replaced with KRBH buffer containing either 2 mM glucose or 20 mM glucose for 1 h. Thereafter, supernatant for the determination of insulin secretory ability and cells for the assay of protein content were collected. Insulin levels were measured using a Human Insulin ELISA Kit (Millipore, Billerica, MA, USA). Cells were lysed with RIPA lysis buffer and the lysates were collected after centrifuged. The BCA™ Protein Assay Kit (Thermo Fisher Scientific) was used to determine protein concentrations. The released insulin level was normalized to total protein content. The relative level of insulin secretion was presented as the ratio of the insulin secretion value to that of the control group at low glucose challenge.
Immunofluorescence analysis
Cells grown in a monolayer were fixed for 20 min in 4% (w/v) paraformaldehyde in PBS at room temperature (RT), washed 3 times with PBS, and blocked for 30 min with 10% (v/v) normal serum (isotypic with the secondary antibodies) in PBS with 0.1% (v/v) Triton X-100 (Sigma-Aldrich). After that, cells were incubated with primary antibodies at 4°C overnight and secondary antibodies for 1 h at RT, followed by washing and staining with DAPI (1 μg/ml, Sigma-Aldrich). Images were captured under a fluorescent microscope (Nikon, Tokyo, Japan). The following antibodies and dilutions were used: rabbit antiFoxO1 (1:200, Cell Signaling Technology), goat anti-Pdx1 (1:400, Abcam), and FITC-conjugated goat anti-rabbit IgG and TRITC-conjugated rabbit anti-goat IgG (both at 1:200 dilution, Zhongshan Biotechnology).
Statistical analysis
Data are expressed as mean ± S.D. Statistical analysis was assessed by SPSS 20.0 for Windows (SPSS Japan Inc., Tokyo, Japan). Comparisons between groups were carried out with a student's t-test or one-way ANOVA tests when appropriate. A P value < 0.05 was considered statistically significant.
Results
The level of cytoplasmic p-FoxO1 protein increases during differentiation of hESCs into IPCs
To evaluate the expression of FoxO1 in hESCs and their progeny cells at different stages of differentiation, we first detected the relative expression levels of FoxO1 mRNA and protein during IPC differentiation of hESCs from stage 1 to stage 5. Differentiated cells from hESCs were generated and harvested according to the modified five-stage DE protocol [11] . FoxO1 expression in the differentiated cells remained almost the same level to hESCs (Fig. 1A and B) . During the IPC differentiation of hESCs, the level of cytoplasmic p-FoxO1 protein increased gradually (Fig. 1C ) and the level of nuclear FoxO1 protein did not show a significant decrease except for stage 5 (Fig. 1D) . The relative expression level of the pluripotency marker Oct4, DE marker Foxa2, gutendoderm marker Hnf1β, pancreatic progenitor marker Pdx1 and β cell marker insulin were analyzed to confirm the corresponding differentiation stage. As shown in Fig. 1E , Oct4 expression level exhibited a drastic decrease from stage 2 and dropped to a very low level at stage 5; the expression level of Foxa2 increased immediately from stage 2 and fell to almost half of the peak value from stage 3 to stage 5; Hnf1β exhibited a peak expression at stage 3; and the expression levels of Pdx1 and insulin were gradually increased significantly from stage 2 to stage 5. These data suggested that the IPCs were successfully generated from hESCs with the modified differentiation protocol. Given that FoxO1 expression level during human foetal pancreatic development was not consistent [17, 18] , we carried out the following gain-and loss-offunction experiments to investigate whether FoxO1 played a role in the IPC differentiation of hESCs.
FoxO1 knockdown promotes, whereas FoxO1 overexpression inhibits, IPC differentiation of hESCs
To determine the role of FoxO1 in the process of IPC differentiation from hESCs, FoxO1 was silenced and overexpressed, respectively. The experimental designs depicting the time points of lentiviral intervention initiation and sample collection were presented in Fig. 2A . Three FoxO1-targeting oligonucleotides were used and LV-si-FoxO1#3 was the most effective for FoxO1 knockdown (Fig. 2B) , which was thus utilized in the following experiments. The mRNA abundance of the transcription factors critical for pancreatic islet cell differentiation, including Foxa2, Ngn3, Nkx6.1, Isl1 and Pdx1, as well as insulin, glucokinase (GK) and glucose transporter 2 (Glut2) was at least doubled after FoxO1 knockdown in the stage-3 cells (pancreatic progenitors). There was no significant change in the mRNA expression level of Oct4 and Hnf1β (Fig. 2C) . Consistently, IPCs derived from pancreatic progenitors with FoxO1 silencing exhibited an elevated insulin secretion under the culture condition with either low or high glucose. The level of insulin secretion at low glucose was 6.25-fold higher in the FoxO1-silencing group than that in the control group, and the level of high glucoseinduced insulin secretion was at least doubled in the FoxO1-silencing group compared with that in the control group (Fig. 2D) . Conversely, overexpression of FoxO1 in the stage-3 cells decreased the level of high glucose-induced insulin secretion from their progeny IPCs. In line with this finding, the expression levels of the markers critical for insulin secretion in response to glucose, including Glut2 and GK were downregulated by FoxO1 overexpression (Fig. 3) . These data suggested that FoxO1 negatively regulated the differentiation kinetics of pancreatic progenitors and intervention targeting FoxO1 expression from stage 3 could influence the insulin secretion capacity of the subsequent IPCs.
Inhibition of FoxO1 promotes the differentiation of hESCs into IPCs
To further investigate the role of FoxO1 during IPC induction without modulating the gene, we treated the stage-3 cells with AS1842856, a selective inhibitor of FoxO1 ( Fig. 2A) . It has been reported that AS1842856 can selectively inhibit the activation of FoxO1, but does not affect the expression level of FoxO1 mRNA and protein in the rat hepatic cell line Fao cells [26] . Similarly, our study did not show any effect of AS1842856 treatment on the expression level of FoxO1 mRNA and protein in the stage-3 cells (Fig. 4A and B) . In accordance with the results of FoxO1 knockdown, the relative expression levels of most of the differentiation markers showed an upward trend after treatment with AS1842856. The mRNA expression levels of Isl1, insulin, GK and Glut2 were almost two-fold increased in the AS1842856 treatment group compared to those in the control group (Fig. 4C) . Most importantly, in agreement with the finding from FoxO1 silencing, inhibition of FoxO1 by AS1842856 in the stage-3 cells doubled the level of high glucose-induced insulin secretion from their progeny IPCs compared with the control group (Fig. 4D) .
Nucleocytoplasmic shuttling of FoxO1 and Pdx1 is involved in the promoting effects of AS1842856 on IPC differentiation of hESCs
To explore the possible mechanism of the promoting effect of the FoxO1 inhibitor AS1842856 on IPC differentiation of hESCs, immunofluorescence analysis was applied to show the subcellular location of FoxO1 and Pdx1. FoxO1 was mainly localized in the nucleus of the stage-3 cells treated by the vehicle (DMSO). Treatment with AS1842856 inhibited nuclear activated FoxO1 and caused cytoplasmic retention of FoxO1 (Fig. 5A) . By contrast, Pdx1 was mainly localized in the cytoplasm of the stage-3 cells that exposed to the control treatment, while it was increasingly localized in the nucleus of the cells treated with AS1842856 (Fig. 5B) . These data indicated that Pdx1 exhibited mutually exclusive nuclear localization with FoxO1 in the hESC-derived pancreatic progenitors. These observations were also confirmed by western blot analysis using the samples isolated from nuclear and cytoplasmic fractions. Treatment with AS1842856 increased cytosolic pFoxO1 protein level and decreased nuclear FoxO1 protein level in the stage-3 cells (Fig. 5C ). In accordance with the finding from immunofluorescence analysis, nuclear Pdx1 protein level almost doubled and cytosolic Pdx1 protein level did not show any significant change in the AS1842856-treated pancreatic progenitors compared with that in the control cells (Fig. 5D) . These results indicated that AS1842856 was involved in the mutually exclusive nucleocytoplasmic shuttling of FoxO1 and Pdx1 by regulating p-FoxO1/FoxO1 status during the differentiation of hESCs into IPCs.
Discussion
There are dissimilarities in islet architecture and function between humans and rodents, though human embryonic pancreatic development can be extrapolated from studies of nonhuman experimental models, especially mice [29] . Recent reports show that differences between the two species were also found in the process of pancreatic development such as delayed appearance and gradual resolution of key differentiation markers [30] . For example, the expression of GATA4 is delayed in human pancreatic development and SOX17 (a DE marker), which exists in the presumptive human pancreatic endoderm, is lost in rodent pancreatic epithelium [31] . Furthermore, there are still knowledge gaps in the developmental process of human pancreatic β cells. It is therefore essentially necessary to utilize appropriate hESC-derived cell models for further understanding of human pancreatic development [32] . In this study, we adopted the DE protocol to differentiate 
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hESCs into IPCs and detected the expression of FoxO1 in all stages. Unlike the reduced level of FoxO1 during induction of human foetal pancreatic precursor cells [17] , the expression level of FoxO1 was quite consistent during IPC differentiation of hESCs. Interestingly, the level of cytoplasmic p-FoxO1 protein increased from stage 1 to stage 5. We speculated that the cytoplasmic localization of FoxO1 might be associated with the IPC differentiation of hESCs, and the unchanged level of FoxO1 expression might be related to immaturity of the differentiated IPCs. Therefore, we carried out loss-and gain-of-function studies to investigate the effect of FoxO1 on this differentiation process. In the present study, FoxO1 knockdown could upregulate the expression level of pancreatic β cell differentiation-related transcription factors and markers such as Nkx6.1, Pdx1, insulin, GK and Glut2 in the stage-3 cells, which might contribute to its promoting effect on GSIS response in their progeny IPCs. Conversely, FoxO1 overexpression downregulated the expression level of insulin, GK and Glut2, and decreased the GSIS response in the IPCs, suggesting that the alteration of FoxO1 expression levels could influence insulin secretion in the hESC-derived IPCs. To our knowledge, this is the first report that FoxO1 can negatively regulate the differentiation of hESCs towards IPCs in vitro. FoxO1 ablation in pancreatic β cells led to impaired insulin secretion and reduced β cell mass following physiologically metabolic stress [33, 34] . FoxO1 protected against metabolic stress-induced β cell failure through induction of NeuroD and MafA, two transcription factors critical for β cell development and maturation [35] . Knockout or knockdown of FoxO1 increased the number of β cells derived from murine pancreatic precursor or enteroendocrine precursor cells [14, 15, 36] . Moreover, FoxO1 inhibition promoted IPC acquirements from human induced pluripotent stem cells derived gut organoid cultures [16] and human foetal pancreatic precursor cells [17, 18] in vitro. These observations indicate that the regulation of expression and activity of FoxO1 at different stages or under diverse conditions is essential for the development, maturation and functional maintenance of pancreatic β cells. Given that in this study genetic manipulation of FoxO1 in the stage-3 cells did influence pancreatic islet differentiation from hESCs, it was of great interest to see whether and how inactivation of FoxO1 worked.
Being a small molecule, AS1842856 can potently inhibit the activity of FoxO1 and its transactivation [26] . It also has the general advantages such as cell permeable, reversible effects on inhibiting the function of the specific protein, flexibility of concentrations and low-cost [37, 38] . It has been reported that phosphorylation/14-3-3 binding is required for rapid nuclear export of FoxO1 [39] . The phosphorylation of FoxO1 at S256 can promote FoxO1 binding to the zeta isoform of 14-3-3 and the binding retains the p-FoxO1 in the cytoplasm, leading to failure of FoxO1 to activate the transcription of its target genes [40, 41] . Likewise, our data showed that AS1842856 induced FoxO1 phosphorylation, leading to nuclear exclusion and thereby downregulating the FoxO1-mediated transactivation of the pancreatic islet differentiation-related genes during the IPC derivation from hESCs. Although AS1842856 treatment did not affect FoxO1 expression level, it induced FoxO1 export from nucleus to cytoplasm and promoted Pdx1 to shuttle into nucleus. Meanwhile, AS1842856 treatment enhanced insulin production and secretion from the hESC-derived IPCs. The results indicated that the AS1842856-induced nuclear FoxO1 export had an effect on the maturation of IPCs and insulin secretion response. In concert with the findings from insulin secretion assay, the expression levels of GK and Glut2 were also upregulated by either AS1842856 treatment or FoxO1 knockdown, indicating that both induction of nuclear FoxO1 export and downregulation of FoxO1 expression may participate in insulin secretion machinery. Whether they are also involved in the recruitment of insulin exocytotic molecules need to be further investigated.
The most prominent role of FoxO1 in adult pancreatic β cells is negative transcriptional regulation of Pdx1 [42, 43] . To explore the possible mechanism involved in the effect that inhibition of FoxO1 by AS1842856 promoted the IPC differentiation of hESCs, we used immunofluorescence and western blot analyses to detect the expression and localization of FoxO1 and Pdx1. Our results showed that after treated with AS1842856, Pdx1 could be found in the nucleus, whereas FoxO1 was localized in the cytoplasm in the pancreatic progenitors derived from hESCs. This exclusive nucleocytoplasmic shuttling pattern was similar to that observed in adult murine β cells [42, 43] . In insulin receptor substrate-2 knockout mice, FoxO1 haploinsufficiency reversed β cell failure by increasing Pdx1 expression [43] . Mice with deletion of 
FoxO1 in the domains of the Pdx1 promoter showed improved glucose tolerance and β cell neogenesis under the condition of high-fat highsucrose feeding [33] . Overexpression of FoxO1 in liver and pancreas of FVB × Bl6 hybrid mice resulted in decreased Pdx1 expression, leading to impaired β cell compensation [44] . In developing human pancreas, FoxO1 and Pdx1 were colocalized within the nucleus and the levels of FoxO1 appeared to be unchanged with prolonged gestational ages [18, 45] . However, FoxO1 protein level in human pancreatic progenitor cells was significantly decreased in a time-dependent manner during in vitro induction [17] . These data suggest that FoxO1 may regulate Pdx1 during human pancreatic development and it may have different roles at different stages of differentiation or under diverse genetic manipulation conditions. In summary, our study demonstrated a previously unidentified role of FoxO1 and its inhibitor AS1842856 in the process of inducing hESCs towards IPCs. We showed that although the expression level of FoxO1 mRNA and protein was unchanged, the phosphorylation of FoxO1 protein was gradually increased in the differentiated cells during the IPC differentiation of hESCs. Inhibition of FoxO1 by either genetic manipulation or pharmacological treatment upregulated the expression level of the transcription factors and markers critical for β cell differentiation, and improved the GSIS response reflecting the maturity of functional IPCs. Conversely, overexpression of FoxO1 resulted in an inhibitory effect on the expression levels of β cell maturation-related markers and the GSIS response. In the hESC-derived pancreatic progenitors treated with AS1842856, the mutually exclusive nucleocytoplasmic pattern of FoxO1 and Pdx1 indicated that inhibition of FoxO1 by AS1842856 promoted Pdx1 transcription, which might explicate the promoting effect of AS1842856 on the IPC differentiation of hESCs. Therefore, our data suggest that inactivation of FoxO1 by small molecules is expected to make an important contribution in the development of more effective cell-based therapies for diabetes. 
